Is X4 Pharmaceuticals, Inc (XFOR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 23.8% / 30% | 31.0% / 30% | 0.5% / 30% | 225.62% / 5% | ✗ NOT HALAL |
| DJIM | 23.8% / 33% | 31.0% / 33% | 0.5% / 33% | 225.62% / 5% | ✗ NOT HALAL |
| MSCI | 53.3% / 33% | 69.7% / 33% | 1.2% / 33% | 225.62% / 5% | ✗ NOT HALAL |
| S&P | 23.8% / 33% | 31.0% / 33% | 0.5% / 33% | 225.62% / 5% | ✗ NOT HALAL |
| FTSE | 53.3% / 33% | 69.7% / 33% | 1.2% / 50% | 225.62% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 83.6% | |
| Operating Margin | -930.6% | |
| Net Margin | -225.6% | |
| Return on Equity (ROE) | -76.0% | |
| Return on Assets (ROA) | -22.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$86M |
| Free Cash Flow | -$89M |
| Total Debt | $77M |
| Debt-to-Equity | 41.5 |
| Current Ratio | 10.2 |
| Total Assets | $290M |
Price & Trading
| Last Close | $4.31 |
| 50-Day MA | $3.70 |
| 200-Day MA | $3.25 |
| Avg Volume | 493K |
| Beta | 0.5 |
|
52-Week Range
$1.35
| |
About X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. It has a license agreement with Abbisko Therapeutics Co Ltd. to manufacture and distribute XOLREMDI in mainland China, Taiwan, Hong Kong and Macau; Norgine to develop, manufacture, and commercialize mavorixafor in Europe, Australia, and New Zealand; and Genzyme Corporation for CXCR4 receptor to develop and commercialize products containing licensed compounds for all therapeutic, prophylactic and diagnostic uses. The company is headquartered in Boston, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is X4 Pharmaceuticals, Inc (XFOR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), X4 Pharmaceuticals, Inc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is X4 Pharmaceuticals, Inc's debt ratio?
X4 Pharmaceuticals, Inc's debt ratio is 23.8% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 53.3%.
What are X4 Pharmaceuticals, Inc's key financial metrics?
X4 Pharmaceuticals, Inc has a market capitalization of $367M, and revenue of $35M. The company maintains a gross margin of 83.6% and a net margin of -225.6%. Return on equity stands at -76.0%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.